Latest News about GILD
Recent news which mentions GILD
2 High-Yielding Stocks You Can Buy and Hold for Years
October 23, 2021
From Motley Fool
Can Merck's Antiviral for COVID Succeed Where Gilead's Failed?
October 23, 2021
From Motley Fool
3 Under-the-Radar COVID Stocks
October 20, 2021
From Motley Fool
2 Tricks and a Treat for Gene Therapy Investors
October 18, 2021
From Motley Fool
2 Top Healthcare Stocks That Could Be Bought Out in 2022
October 16, 2021
From Motley Fool
This Company Revolutionizes What Matters for Hospitals, Big Pharma and Health Insurers
October 14, 2021
From Benzinga
From InvestorPlace
Why CRISPR Therapeutics Stock Is Sinking Today
October 13, 2021
From Motley Fool
Molnupiravir? Not So Fast. What About Tollovir? — Here's Why You Should Know What That Means
October 12, 2021
From Benzinga
Moderna Stock Looks Fully Valued Here, But It Has a Great Future
October 08, 2021
From InvestorPlace
Merck May Beat Pfizer to the COVID Pill Market. Does It Matter?
October 06, 2021
From Motley Fool
From Motley Fool
Could Pfizer's COVID Pill Be Better Than Merck's?
October 06, 2021
From Motley Fool
NanoViricides Leaps Forward in its Quest to Defeat COVID-19
October 05, 2021
From Benzinga
Tesla and Merck Give Investors Some Hope
October 04, 2021
From Benzinga
From Benzinga
This Healthcare Company Is Using AI to Develop Drugs
October 03, 2021
From Motley Fool
From Benzinga
From MarketWatch
Gilead's Kite Files US Application To Expand Use Of Yescarta In Second-Line Setting
October 01, 2021
Tickers
GILD
From Benzinga
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
October 01, 2021
From Benzinga
3 Top Dividend Stocks Yielding More Than 4%
September 30, 2021
From Motley Fool
Merck's COVID-19 Antiviral Pill Effective Against Variants, Lab Studies Show
September 29, 2021
From Benzinga
GSK, Pfizer Backed Long-Acting HIV Med Under FDA Priority Review As Preventative Option
September 28, 2021
From Benzinga
Gilead Scores Fifth Approval For Trodelvy In Triple-Negative Breast Cancer, This Time In Canada
September 28, 2021
Tickers
GILD
From Benzinga
Pfizer Begins Late-Stage Study To Test Effectiveness Of Oral Drug Against COVID-19 In Those Exposed To The Virus
September 28, 2021
From Benzinga
3 COVID Stocks Ready to Take On the Delta Variant
September 27, 2021
From Motley Fool
Acceleron In Advanced $11B Buyout Talks: Bloomberg
September 27, 2021
From Benzinga
7 Members Of Congress Failed To Disclose Stock Transactions: Who Was Named, And What's Next?
September 24, 2021
From Benzinga
3 Relatively Safe Pharma Stocks You Can Buy Right Now
September 23, 2021
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.